Study of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer (OVATION 2)
← catalyst calendarSponsored by Imunon (industry) · IMNN — their whole pipeline →.
Phase
Phase 1/2
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
130estimated
Sites
21
Countries
Canada, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2018-09-05 | actual | When the study began enrolling |
| Primary completion | 2024-07-25 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-05-30 | estimated | The whole study's end, after follow-up |
| First posted | 2018-01-09 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-04 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Epithelial Ovarian Cancer
- Fallopian Tube Cancer
- Primary Peritoneal Cancer
Interventions
- Biological: IMNN-001
- Drug: Carboplatin
- Drug: Paclitaxel
Primary outcome
what the primary-completion date above is the date OFPFS
measured The primary analysis for PFS will be conducted after at least 80 events have been observed or after all patients have been followed for at least 16 months, whichever is later.
Publications
- PMID 40461366 — linked by the registry
- PMID 36608308 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · IMNN's whole pipeline · Catalyst calendar · Every registered study · What changed